Lobbying Information
Subject Matters
- Health
- Industry
- Intellectual Property
Subject matters added through a monthly communication report
- Internal Trade
- International Trade
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Industry Canada regarding export provisions of the Patent Act.
- Industry Canada with respect to the Patent Act as it pertains to pharmaceuticals.
- Modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals.
Policies or Program
- Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
- Health Canada, Industry Canada, and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
- Science and Technology Strategy regarding the need for a balanced Intellectual Property (IP) regime and the important role competition plays in encouraging innovation.
- The development and implementation of an approval pathway for Subsequent Entry Biologics (SEBs).
Regulation
- Amendments to the Patented Medicines (Notice of Compliance) Regulations with regard to section 8 of the regulations, the inclusion of a mechanism that would prevent a brand company from suing a generic company twice on the same patent and an administrative change to explicitly allow a generic company to amend a Notice of Allegation.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Health Canada (HC)
-
Industry Canada
-
Prime Minister's Office (PMO)
Government institutions added through a monthly communication report
- House of Commons
- Senate of Canada
In-house Corporation Details
Description of activities
Cobalt is a fully integrated organization, focused primarily on generic pharmaceutical products.
Responsible officer name and position during the period of this registration
Terry Fretz,
Chief Executive Officer
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
6500 Kitimat Road
Mississauga, ON L5N 2B8
Canada
Telephone number:
905-363-6775
Fax number:
905-814-8722
Parent Company Information
- Arrow Pharmaceuticals Inc.
-
6500 Kitimat Road
Mississauga, ON L5N 2B8
Canada
Subsidiary Beneficiary Information
Cobalt Pharmaceuticals Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Terry Fretz,
President |
No public offices held
- Henry Koziarski,
Chief Financial Officer |
No public offices held
- Connie Lin,
Director Regulatory Affairs |
No public offices held
- Tirtho Uppal,
Vice President Regulatory Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Jane Farnham-Verway,
Vice President, Corporate Affairs |
No public offices held